331 related articles for article (PubMed ID: 22105720)
1. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
2. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Wadler S; Makower D; Clairmont C; Lambert P; Fehn K; Sznol M
J Clin Oncol; 2004 May; 22(9):1553-63. PubMed ID: 15117978
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule.
Feun L; Modiano M; Lee K; Mao J; Marini A; Savaraj N; Plezia P; Almassian B; Colacino E; Fischer J; MacDonald S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):223-9. PubMed ID: 12203104
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Yen Y; Margolin K; Doroshow J; Fishman M; Johnson B; Clairmont C; Sullivan D; Sznol M
Cancer Chemother Pharmacol; 2004 Oct; 54(4):331-42. PubMed ID: 15148626
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors.
Schelman WR; Morgan-Meadows S; Marnocha R; Lee F; Eickhoff J; Huang W; Pomplun M; Jiang Z; Alberti D; Kolesar JM; Ivy P; Wilding G; Traynor AM
Cancer Chemother Pharmacol; 2009 May; 63(6):1147-56. PubMed ID: 19082825
[TBL] [Abstract][Full Text] [Related]
6. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Choi BS; Alberti DB; Schelman WR; Kolesar JM; Thomas JP; Marnocha R; Eickhoff JC; Ivy SP; Wilding G; Holen KD
Cancer Chemother Pharmacol; 2010 Oct; 66(5):973-80. PubMed ID: 20127092
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Attia S; Kolesar J; Mahoney MR; Pitot HC; Laheru D; Heun J; Huang W; Eickhoff J; Erlichman C; Holen KD
Invest New Drugs; 2008 Aug; 26(4):369-79. PubMed ID: 18278438
[TBL] [Abstract][Full Text] [Related]
11. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.
Kunos CA; Chu E; Beumer JH; Sznol M; Ivy SP
Cancer Chemother Pharmacol; 2017 Jan; 79(1):201-207. PubMed ID: 27878356
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
14. A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation.
Fyfe D; Raynaud F; Langley RE; Newell DR; Halbert G; Gardner C; Clayton K; Woll PJ; Judson I; Carmichael J
Cancer Chemother Pharmacol; 2002 Jan; 49(1):1-6. PubMed ID: 11855748
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Odenike OM; Larson RA; Gajria D; Dolan ME; Delaney SM; Karrison TG; Ratain MJ; Stock W
Invest New Drugs; 2008 Jun; 26(3):233-9. PubMed ID: 18217206
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.
Heath EI; Bible K; Martell RE; Adelman DC; Lorusso PM
Invest New Drugs; 2008 Feb; 26(1):59-65. PubMed ID: 17938863
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.
Kunos CA; Waggoner S; von Gruenigen V; Eldermire E; Pink J; Dowlati A; Kinsella TJ
Clin Cancer Res; 2010 Feb; 16(4):1298-306. PubMed ID: 20145183
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Ocean AJ; Christos P; Sparano JA; Matulich D; Kaubish A; Siegel A; Sung M; Ward MM; Hamel N; Espinoza-Delgado I; Yen Y; Lane ME
Cancer Chemother Pharmacol; 2011 Aug; 68(2):379-88. PubMed ID: 20981545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
